Medtronic forks out $85m to settle shareholder action over Infuse off-label fallout
This article was originally published in Clinica
Executive Summary
Medtronic has paid $85m to resolve a federal securities class action over claims that it promoted its Infuse bone graft product for unapproved uses, which falsely inflated the firm's share price.